AgeneBio
is a biotechnology company that develops and commercializes CNS therapeutics for the treatment of neurological and psychiatric diseases... Read moreAgeneBio
is a biotechnology company that develops and commercializes CNS therapeutics for the treatment of neurological and psychiatric diseases... Read more
News
Feb 24, 2026
Pulse2.0
AgeneBio: AgeneBio: Northwestern University Research On Levetiracetam Plaque Prevention Reinforces Novel Alzheimer's Disease Approach
Apr 21, 2021
Markets Insider
AgeneBio: AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease
Sep 11, 2019
PR Newswire
Press Release: AgeneBio : AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer's and Other CNS Conditions
Jan 21, 2019
BioPortfolio
AgeneBio: AgeneBio begins patient enrollment in phase 3 trial to evaluate AGB101 to treat MCI due to AD
Jan 21, 2019
Pharmabiz
AgeneBio: AgeneBio begins patient enrollment in phase 3 trial to evaluate AGB101 to treat MCI due to AD
Oct 09, 2018
PharmiWeb
AgeneBio: AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer's Disease
Aug 29, 2018
BioPortfolio
AgeneBio: AgeneBio Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250
Jun 28, 2018
FierceBiotech
AgeneBio: Neos poaches AgeneBio chief as CEO Vipin Garg abruptly resigns
May 01, 2018
BioPortfolio
AgeneBio: AgeneBio Founder Dr. Michela Gallagher participates in the 2018 Milken Global Conference
Dec 01, 2017
BioPortfolio
AgeneBio: AgeneBio Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 08112017 Prices from USD $250
AgeneBio Competitors
1
2
3
4
5
6
7
8
9
10